Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases
Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases
复制标题
DOI：
10.1016/j.coph.2018.05.010
复制
发表时间：
2018-08-01
影响因子：
4
通讯作者：
Scott, Andrew M.
中科院分区：
文献类型：
--
作者：
Hafeez, Umbreen;Gan, Hui K.;Scott, Andrew M.
自1906年诺贝尔奖获得者保罗·埃利希提出魔术子弹的概念，1975年科勒和米尔斯坦发现杂交技术，1988年格雷格·温特开创了将单克隆抗体人源化的技术以来，单克隆抗体已被成功开发用于治疗医学疾病。单克隆抗体是抑制同种免疫反应性、血液恶性肿瘤、实体器官恶性肿瘤、病毒性疾病的有效治疗方法，也可用作抗血小板治疗。它们在人类癌症和自身免疫性疾病中的成功应用使其成为过去几十年中批准用于这些适应症的增长最快的新药之一。本文综述了单克隆抗体作为免疫调节治疗癌症和自身免疫性疾病的作用，用于提高疗效的策略，以及如何解决耐药机制，以改善患者的治疗结果。
Since Nobel laureate Paul Ehrlich proposed the concept of magic bullet in 1906, Kohler and Milstein discovered Hybridoma technology in 1975, and Greg Winter pioneered the technique to humanize monoclonal antibodies in 1988, monoclonal antibodies have been successfully developed to treat medical illnesses. Monoclonal antibodies are effective treatments for inhibition of alloimmune reactivity, haematological malignancies, solid organ malignancies, viral illnesses and are also used as antiplatelet therapy. Their successful use in cancer and autoimmune diseases in humans have made them one of the fastest growing classes of new drugs approved for these indications in last few decades. This review focuses on the role of monoclonal antibodies as an immunomodulatory therapy against cancer and autoimmune diseases, the strategies used to enhance efficacy, and how resistance mechanisms are being addressed to improve therapeutic outcomes for patients.